Tobin Strom1, Michael Carr2, Jonathan S Zager3,4, Arash Naghavi1, Franz O Smith3,4, C Wayne Cruse3,4, Jane L Messina3,5, Jeffery Russell6, Nikhil G Rao1, William Fulp7, Sungjune Kim1, Javier F Torres-Roca1, Tapan A Padhya6, Vernon K Sondak3,4, Andy M Trotti1, Louis B Harrison8, Jimmy J Caudell9. 1. Department of Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. 2. School of Medicine, University of South Florida Morsani College of Medicine, Tampa, FL, USA. 3. Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA. 4. Departments of Oncologic Sciences and Surgery, University of South Florida Morsani College of Medicine, Tampa, FL, USA. 5. Departments of Pathology & Cell Biology and Dermatology, University of South Florida Morsani College of Medicine, Tampa, FL, USA. 6. Department of Head and Neck and Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA. 7. Department of Biostatistics, Moffitt Cancer Center, Tampa, FL, USA. 8. Department of Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. louis.harrison@moffitt.org. 9. Department of Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. jimmy.caudell@moffitt.org.
Abstract
BACKGROUND: Following wide excision of Merkel cell carcinoma (MCC), postoperative radiation therapy (RT) is typically recommended. Controversy remains as to whether RT can be avoided in selected cases, such as those with negative margins. Additionally, there is evidence that RT can influence survival. METHODS: We included 171 patients treated for non-metastatic MCC from 1994 through 2012 at a single institution. Patients without pathologic nodal evaluation (clinical N0 disease) were excluded to reflect modern treatment practice. The endpoints included local control (LC), locoregional control (LRC), disease-free survival (DFS), overall survival (OS), and disease-specific survival (DSS). RESULTS: Median follow-up was 33 months. Treatment with RT was associated with improved 3-year LC (91.2 vs. 76.9 %, respectively; p = 0.01), LRC (79.5 vs. 59.1 %; p = 0.004), DFS (57.0 vs. 30.2 %; p < 0.001), and OS (73 vs. 66 %; p = 0.02), and was associated with improved 3-year DSS among node-positive patients (76.2 vs. 48.1 %; p = 0.035), but not node-negative patients (90.1 vs. 80.8 %; p = 0.79). On multivariate analysis, RT was associated with improved LC [hazard ratio (HR) 0.18, 95 % confidence interval (CI) 0.07-0.46; p < 0.001], LRC (HR 0.28, 95 % CI 0.14-0.56; p < 0.001), DFS (HR 0.42, 95 % CI 0.26-0.70; p = 0.001), OS (HR 0.53, 95 % CI 0.31-0.93; p = 0.03), and DSS (HR 0.42, 95 % CI 0.26-0.70; p = 0.001). Patients with negative margins had significant improvements in 3-year LC (90.1 vs. 75.4 %; p < 0.001) with RT. Deaths not attributable to MCC were relatively evenly distributed between the RT and no RT groups (28.5 and 29.3 % of patients, respectively). CONCLUSIONS: RT for MCC was associated with improved LRC and survival. RT appeared to be beneficial regardless of margin status.
BACKGROUND: Following wide excision of Merkel cell carcinoma (MCC), postoperative radiation therapy (RT) is typically recommended. Controversy remains as to whether RT can be avoided in selected cases, such as those with negative margins. Additionally, there is evidence that RT can influence survival. METHODS: We included 171 patients treated for non-metastatic MCC from 1994 through 2012 at a single institution. Patients without pathologic nodal evaluation (clinical N0 disease) were excluded to reflect modern treatment practice. The endpoints included local control (LC), locoregional control (LRC), disease-free survival (DFS), overall survival (OS), and disease-specific survival (DSS). RESULTS: Median follow-up was 33 months. Treatment with RT was associated with improved 3-year LC (91.2 vs. 76.9 %, respectively; p = 0.01), LRC (79.5 vs. 59.1 %; p = 0.004), DFS (57.0 vs. 30.2 %; p < 0.001), and OS (73 vs. 66 %; p = 0.02), and was associated with improved 3-year DSS among node-positive patients (76.2 vs. 48.1 %; p = 0.035), but not node-negative patients (90.1 vs. 80.8 %; p = 0.79). On multivariate analysis, RT was associated with improved LC [hazard ratio (HR) 0.18, 95 % confidence interval (CI) 0.07-0.46; p < 0.001], LRC (HR 0.28, 95 % CI 0.14-0.56; p < 0.001), DFS (HR 0.42, 95 % CI 0.26-0.70; p = 0.001), OS (HR 0.53, 95 % CI 0.31-0.93; p = 0.03), and DSS (HR 0.42, 95 % CI 0.26-0.70; p = 0.001). Patients with negative margins had significant improvements in 3-year LC (90.1 vs. 75.4 %; p < 0.001) with RT. Deaths not attributable to MCC were relatively evenly distributed between the RT and no RT groups (28.5 and 29.3 % of patients, respectively). CONCLUSIONS: RT for MCC was associated with improved LRC and survival. RT appeared to be beneficial regardless of margin status.
Authors: Matthew C Perez; Daniel E Oliver; Evan S Weitman; David Boulware; Jane L Messina; Javier Torres-Roca; C Wayne Cruse; Ricardo J Gonzalez; Amod A Sarnaik; Vernon K Sondak; Evan J Wuthrick; Louis B Harrison; Jonathan S Zager Journal: Ann Surg Oncol Date: 2018-10-11 Impact factor: 5.344
Authors: Maclean M Cook; Stephanie K Schaub; Peter H Goff; Alex Fu; Song Y Park; Daniel S Hippe; Jay J Liao; Smith Apisarnthanarax; Shailender Bhatia; Yolanda D Tseng; Paul T Nghiem; Upendra Parvathaneni Journal: Adv Radiat Oncol Date: 2020-07-21
Authors: Matthew C Perez; Felipe R de Pinho; Amanda Holstein; Daniel E Oliver; Syeda M H Naqvi; Youngchul Kim; Jane L Messina; Erin Burke; Ricardo J Gonzalez; Amod A Sarnaik; C Wayne Cruse; Evan J Wuthrick; Louis B Harrison; Vernon K Sondak; Jonathan S Zager Journal: Ann Surg Oncol Date: 2018-08-02 Impact factor: 5.344
Authors: Christopher K Bichakjian; Thomas Olencki; Sumaira Z Aasi; Murad Alam; James S Andersen; Rachel Blitzblau; Glen M Bowen; Carlo M Contreras; Gregory A Daniels; Roy Decker; Jeffrey M Farma; Kris Fisher; Brian Gastman; Karthik Ghosh; Roy C Grekin; Kenneth Grossman; Alan L Ho; Karl D Lewis; Manisha Loss; Daniel D Lydiatt; Jane Messina; Kishwer S Nehal; Paul Nghiem; Igor Puzanov; Chrysalyne D Schmults; Ashok R Shaha; Valencia Thomas; Yaohui G Xu; John A Zic; Karin G Hoffmann; Anita M Engh Journal: J Natl Compr Canc Netw Date: 2018-06 Impact factor: 12.693
Authors: Nazanin Yeganeh Kazemi; Christopher Jain; Melanie C Bois; Atta Behfar; Kenneth Olivier; Svetomir N Markovic Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2019-11-22
Authors: Karolina Stachyra; Monika Dudzisz-Śledź; Elżbieta Bylina; Anna Szumera-Ciećkiewicz; Mateusz J Spałek; Ewa Bartnik; Piotr Rutkowski; Anna M Czarnecka Journal: Int J Mol Sci Date: 2021-06-11 Impact factor: 5.923
Authors: Rafael A Schmerling; Jose G Casas; Gabriela Cinat; Fabio Ernesto Grosso Ospina; Luiza E B P Kassuga; Jorge Luis Martinez Tlahuel; Luis Daniel Mazzuoccolo Journal: J Glob Oncol Date: 2018-07